TRLV vs USNA
Trulieve Cannabis Corp. and Usana Health Sciences Inc., side by side — 7 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | TRLV | USNA |
|---|---|---|
| Revenue | $1.2B | $925.3M |
| Net income | $-122.2M | $10.8M |
| Gross margin | 60.2% | 78.3% |
| Net margin | −10.3% | 1.2% |
| Return on equity | −10.2% | 2.0% |
| Diluted EPS | −$0.58 | $0.58 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $228.6M | $8.5M |
| Equity | · | $533.1M |
| Net debt / equity | −0.10× | · |
| Current ratio | 4.43× | 2.24× |
| Revenue CAGR 5y | 17.8% | −4.0% |
| Profit CAGR 5y | · | −38.7% |
TRLV bills 1.3× the revenue of USNA, and TRLV closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
7 years side by side
| Fiscal year | TRLV | USNA |
|---|---|---|
| FY2025 | $1.2B | $925.3M |
| FY2024 | $1.2B | $854.5M |
| FY2023 | $1.1B | $921.0M |
| FY2022 | $1.2B | $998.6M |
| FY2021 | $931.9M | $1.2B |
| FY2020 | $521.5M | $1.1B |
| FY2019 | $252.8M | $1.1B |
Bottom line
| Fiscal year | TRLV | USNA |
|---|---|---|
| FY2025 | $-122.2M | $10.8M |
| FY2024 | $-160.6M | $42.0M |
| FY2023 | $-533.1M | $63.8M |
| FY2022 | $-252.7M | $69.3M |
| FY2021 | $17.4M | $116.5M |
| FY2020 | $63.0M | $124.7M |
| FY2019 | $53.1M | $100.5M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$255,923,000 | TRLV |
| FY2024 | +$331,987,000 | TRLV |
| FY2023 | +$208,183,000 | TRLV |
| FY2022 | +$219,628,000 | TRLV |
| FY2021 | −$254,530,000 | USNA |
| FY2020 | −$613,111,000 | USNA |
| FY2019 | −$808,083,000 | USNA |
The higher-revenue side has changed between TRLV and USNA over this period. The gap has narrowed since the earliest year compared.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −11.6 pp | USNA |
| FY2024 | −18.5 pp | USNA |
| FY2023 | −54.1 pp | USNA |
| FY2022 | −27.7 pp | USNA |
| FY2021 | −7.9 pp | USNA |
| FY2020 | +1.1 pp | TRLV |
| FY2019 | +11.5 pp | TRLV |
The higher net margin has changed hands between TRLV and USNA over this period.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TRLV's net margin has been more volatile than USNA's over the 7 comparable fiscal years — 21.0 percentage points of standard deviation against 3.1.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between TRLV and USNA over these 7 fiscal years — TRLV led in 2 and USNA in 5.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TRLV's return on equity has been more volatile than USNA's over the 7 comparable fiscal years — 22.3 percentage points of standard deviation against 10.2.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between TRLV and USNA over these 7 fiscal years — TRLV led in 1 and USNA in 6.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.